Part, Chapter, Paragraph
1 -, 1 | status of health through selected indicators and their trends
2 II, 4. 2 | shows the contribution of 13 selected causes of death to the increase
3 II, 4. 2 | expectancy by cause of death for selected EU countries for the periods
4 II, 4. 2 | 2000. These countries were selected on the basis of availability
5 II, 4. 2 | birth by cause of death, selected countries.~ ~In most EU
6 II, 4. 2 | for men in 7 out of the 13 selected countries the decline in
7 II, 4. 2 | expectancy at birth 1980-2000, selected countries~ ~Table 4.2.5
8 II, 4. 2 | for men in 8 out of the 13 selected countries and for women
9 II, 4. 2 | life expectancy at birth, selected countries.~ ~The decline
10 II, 4. 2 | life expectancy at 65 for selected EU countries. Only countries
11 II, 4. 2 | successive decades were selected.~ ~Table 4.2.6. Average
12 II, 4. 2 | in life expectancy at 65, selected countries.~ ~Table 4.2.6
13 II, 4. 2 | that in 11 out of the 17 selected countries the increase in
14 II, 4. 2 | expectancy at the age of 80, selected countries.~ ~The conclusion
15 II, 5. 1. 1 | important at population level selected from WHO HFA database (htt 7)
16 II, 5. 2. 2 | ten years (1994-2003) were selected to estimate mortality trends.
17 II, 5. 2. 2 | at population level were selected: hypertension, hypercholesterol,
18 II, 5. 3. 1 | incident cases and deaths by selected cancer sites in EU25 (2006).~ ~
19 II, 5. 3. 3 | presented here subdivided per selected cancer site: stomach (ICD-9
20 II, 5. 3. 3 | indicator is available for selected European countries from
21 II, 5. 4. 2 | average results obtained on a selected population, but their results
22 II, 5. 4. 6 | the EU requires carefully selected indicators, which should
23 II, 5. 5. 2 | people with dementia in selected EUGLOREH countries~ ~The
24 II, 5. 5. 3 | comparison data on mortality for selected causes of death are not
25 II, 5. 5. 3 | absolute number of deaths in selected countries with respect to
26 II, 5. 5. 3 | et al, 2004) worldwide; selected data of studies from Western
27 II, 5. 5. 3 | different from those of selected populations followed during
28 II, 5. 5. 3 | employment have been performed in selected clinical samples and differing
29 II, 5. 5. 3 | of Multiple Sclerosis in selected EUGLOREH Countries~ ~Table
30 II, 5. 5. 3 | of Multiple Sclerosis in selected EUGLOREH Contries by gender~ ~
31 II, 5. 5. 3 | of Multiple Sclerosis in selected EUGLOREH Countries, by age (
32 II, 5. 5. 3 | patients by disease course in selected EUGLOREH countries~The distribution
33 II, 5. 5. 3 | disease severity (EDSS) in selected EUGLOREH countries~ ~MS
34 II, 5. 5. 3 | 100 000) of MS patients in selected EUGLOREH countries~ ~The
35 II, 5. 5. 3 | of Parkinson’s disease in selected EUGLOREH countries~Incidence
36 II, 5. 5. 3 | Cost per case in PD in selected EUGLOREH countries (€PPP,
37 II, 5. 5. 3 | and of similar design were selected for this analysis. No studies,
38 II, 5. 5. 3 | Parkinson’s disease has been selected as one of the key diseases.
39 II, 5. 6. 3 | Osteoarthritis Incidence in selected European countries~ ~Table
40 II, 5. 6. 3 | Osteoarthritis Prevalence in selected EUGLOREH Countries~ ~Table
41 II, 5. 6. 3 | Radiographic Criteria) in selected European Countries ~ ~Figure
42 II, 5. 6. 6 | prevalence of arthritis and selected musculoskeletal disorders
43 II, 5. 7. 3 | chronic kidney disease in selected EUGLOREH countries.~ ~Figure
44 II, 5. 9. 4 | Survey I showed that seven selected allergens (Dermatophagoides
45 II, 5. 9. 4 | in vitro systems and on selected target cells. Provocation
46 II, 5. 10. 3 | Intervals per country in selected EUGLOREH countries~ ~Prevalence
47 II, 5. 11. 3 | disease.~ ~Prevalence of selected dermatological diseases
48 II, 5. 11. 3 | Table 5.11.1. Prevalence of selected dermatological diseases~ ~
49 II, 5. 12. 2 | of ethanol per year) for selected countries were derived from
50 II, 5. 12. 3 | the 1970-2002 period in selected European countries are given
51 II, 5. 12. 3 | mortality rates in men from selected EUGLOREH countries, 1970-
52 II, 5. 12. 3 | mortality rates in women from selected EUGLOREH countries, 1970-
53 II, 5. 12. 3 | mortality from the disease in selected countries (de la Pena et
54 II, 5. 12. 6 | mainly in very advanced and selected (i.e. comparatively younger)
55 II, 5. 14. 3 | 12 year-old children in selected EUGLOREH countries~ ~Such
56 II, 5. 14. 3 | Edentulous people aged 65 in selected EUGLOREH countries~ ~The
57 II, 5. 14. 3 | Assessment (Pocket >6mm) in selected EUGLOREH countries~ ~Untreated,
58 II, 5. 15. 4 | Neurological diseases) have been selected for funding. They will serve
59 II, 6. 3. 2 | blood stream infections in selected EUGLOREH Countries.~ ~For
60 II, 6. 3. 4 | vaccination coverage in these selected groups, but also by adopting
61 II, 6. 3. 4 | countries.~ ~Annex 6.1. Selected tables and figures from
62 II, 6. 3. 4 | A1.1 TB cases per 100,000 selected countries and EU 25~Figure
63 II, 7. 2. 2 | available by country, sex and selected ICD codes at EuroStat (information
64 II, 7. 2. 6 | Emergency department data from selected Member State hospitals.
65 II, 7. 2. 8 | Interview Survey (ECHIS) selected indicators on injuries are
66 II, 7. 3. 2 | Figure 7.4).~ ~Figure 7.4. Selected causes of fatal injuries,
67 II, 7. 3. 5 | suicide attempts by sex, selected EUGLOREH countries~ ~This
68 II, 7. 3. 5 | Homicide, assault by sex selected EUGLOREH countries).~ ~Figure
69 II, 7. 3. 5 | Homicide, assault by sex selected EUGLOREH countries~ ~The
70 II, 7. 4 | Subsets of this list could be selected for further development
71 II, 7. 4. 5 | home and leisure accidents, selected EUGLOREH countries~ ~Analyses
72 II, 8. 2. 1 | opportunities9. The Group have selected the WHO’s ICF (2001) as
73 II, 8. 2. 2 | in each WHO region were selected for intensified assistance,
74 II, 8. 2. 3 | carried out in 590 randomly selected Swedish subjects aged from
75 II, 9. 1. 1 | and infant mortality in selected EUGLOREH countries~ ~
76 II, 9. 1. 1 | plurality~R: Prevalence of selected congenital anomalies~R:
77 II, 9. 1. 1 | Infant mortality by cause in selected EUGLOREH countries in 2005
78 II, 9. 1. 1 | per 1 000 live births in selected EUGLOREH countries, birth
79 II, 9. 1. 1 | cases, born 1990-1998, in selected EUGLOREH countries~ ~Cerebral
80 II, 9. 1. 2 | Mastroiacovo P (2006): "Trends of Selected Malformations in Relation
81 II, 9. 2. 3 | in children aged 0-14 in selected EUGLOREH Countries – Boys~ ~
82 II, 9. 2. 3 | in children aged 0-14 in selected EUGLOREH Countries – Girls~ ~
83 II, 9. 3. 1 | 1 Premature mortality by selected causes of deaths in EU,
84 II, 9. 3. 1 | Prevalence And Incidence Of Selected Curable Sexually Transmitted
85 II, 9. 3. 2 | Maternal mortality ratio in selected EUGLOREH countries in 2004-
86 II, 9. 3. 2 | These indicators were not selected for the EURO-PERISTAT set
87 II, 9. 4. 3 | in trials, but tend to be selected because they are particularly
88 II, 9. 5. 3 | deaths for men and women for selected EUGLOREH countries~ ~Economic
89 II, 9. 5. 3 | patterns for men and women in selected EU countries. While a high
90 II, 9. 5. 3 | patterns among men and women in selected European countries~ ~Figure
91 III, 10. 1 | simplified scenarios involving selected determinants and their interrelationship (
92 III, 10. 1. 3 | Murray CJL et al (2002): Selected major risk factors and global
93 III, 10. 2. 1 | 10.2.1.1.3. Deaths from selected causes (%), attributable
94 III, 10. 2. 1 | Bank.~ ~Table 10.2.1.1.4. Selected EUGLOREH countries and total
95 III, 10. 2. 1(5)| See EMCDDA’s 2006 selected issues on drug use in recreational
96 III, 10. 2. 1 | from various studies in selected EU Countries for young adults (
97 III, 10. 2. 1 | chapter (Fig. 2 and 3).~ ~Selected multicentre studies~ ~-
98 III, 10. 2. 1 | aged 11, 13 and 15 years, selected countries in the WHO European
99 III, 10. 2. 1 | designs, dietary methods and selected population descriptors.
100 III, 10. 2. 1 | will be validated in five selected countries with obviously
101 III, 10. 2. 1 | vegetables and fruits and of some selected products is reported in
102 III, 10. 2. 1 | apparent consumption of some selected products, 2004 (1 000 t)~ ~
103 III, 10. 2. 1 | of disease attribution to selected major risk factors. Vol.
104 III, 10. 2. 1 | estimated prevalence of selected cardiovascular and related
105 III, 10. 4. 2 | the official control of selected contaminants:~ ~• Commission
106 III, 10. 4. 2 | Exposure (MOE), i.e. the point selected on the dose-response curve
107 III, 10. 4. 3 | information from eight selected European countries shows
108 III, 10. 4. 3 | water-borne outbreaks in selected countries, 2000–2005~ ~The
109 III, 10. 4. 3 | wastewater treatment facilities, selected European countries,1980-
110 III, 10. 4. 3 | water. Priority diseases selected for target setting and reporting
111 III, 10. 4. 3 | disease attributable to selected environmental factors and
112 III, 10. 4. 5 | Hazardous waste generation in selected EU-25+EFTA, SEE and EECCA
113 III, 10. 5. 1 | leisure accidents per year in selected EU countries).~ ~Floor space
114 III, 10. 5. 1 | priority themes. These themes, selected in conjunction with stakeholders,
115 III, 10. 5. 2 | settlement structure in 2003 for selected EUGLOREH countries~ ~Thereby,
116 III, 10. 5. 2 | Percentage and total number of selected STI episodes in general
117 III, 10. 5. 3 | compensation schemes in selected EU Countries has been carried
118 III, 10. 5. 3 | who have a poor health are selected for the pool of the unemployed.
119 III, 10. 6. 1 | and their time-trends in selected EU countries~ ~However,
120 III, 10. 6. 2 | inequalities in mortality in selected European Countries per cause~ ~
121 IV, 11. 1. 5 | in the initial OECD were selected on the basis of scientific
122 IV, 11. 1. 6 | allowance, fee-for-service for selected services, target payments
123 IV, 11. 6. 4 | available to compute the selected outcome indicators, the
124 IV, 11. 6. 4 | available for most of the selected diseases, whereas clinical
125 IV, 12. 2 | Policies and control tools for selected diseases~Cardiovascular
126 IV, 12. 2 | control tools as applied to selected health determinants~ ~1.
127 IV, 12. 5 | disability-free at age 65 years for selected EU Member States - men.~ ~
128 IV, 12. 5 | disability-free at age 65 years for selected EU Member States - women.~ ~
129 IV, 12. 8 | one third of all projects selected in 2005. The EEA and Norway’
130 IV, 12. 10 | Policy documents adopted by selected Member States is given in
131 IV, 12. 10 | disposal~High~Regional~ Yes~Selected chemical contaminants~High ~
132 IV, 12. 10 | and waste disposal~ High~ ~Selected chemical contaminants~ High~ ~
133 IV, 12. 10 | reporting (see www.rki.de).~ Selected activities:~National campaign “
134 IV, 12. 10 | their subsequent use.~ ~Selected chemical contaminants~High
135 IV, 12. 10 | Specific Information on selected conditions and their treatment
136 IV, 12. 10 | participation by the public.~Selected chemical contaminants~High~
137 IV, 12. 10 | provides an overview of selected key trends in health in
138 IV, 12. 10 | have been placed in various selected points and keep the bag
139 IV, 12. 10 | recycling program of batteries~Selected chemical contaminants~ High~
140 IV, 12. 10 | environment 2003-2008 http ~ ~Selected chemical contaminants~ high~
141 IV, 12. 10 | national Public Health Strategy~Selected chemical contaminants~intermediate~Law ~ ~
142 IV, 12. 10 | implementation of clinical waste plan~Selected chemical contaminants~ ~ ~ -
143 IV, 12. 10 | campaign for children~http df~Selected chemical contaminants~intermediate~
144 IV, 12. 10 | Information is given below about selected determinants concerning
145 IV, 12. 10 | disposal~Intermediate~ ~ ~Selected chemical contaminants~High~
146 IV, 13. 1 | 13.1. Differences in selected mortality indicators among
147 IV, 13. 1 | Standardised Death Rates for selected non-communicable causes
148 IV, 13. 2. 2 | of burden of diseases and selected health determinants~· In
149 IV, 13. 2. 3 | of disease in 2000 due to selected health determinants for
150 IV, 13. 2. 3 | have been calculated for 49 selected conditions. Table 13.7 presents
151 IV, 13. 9 | Murray CJL et al (2002): Selected major risk factors and global
